After chemotherapy, the patients with acute leukemia often accompany with severe thrombocytopenia, and it is difficult to be prevented and treated. For a long time, platelet transfusion is
always the standard therapeutic method for severe thrombocytopenia with definite efficacy. But the platelets have short storage time, nervous sources, and can occur transfusion
reaction, which restrict its clinical application.
Full-length glycosylation recombinant human thrombopoietin (rhTPO) is mainly used for the treatment in thrombocytopenia caused after tumor chemotherapy. We observed the clinical efficacy and adverse reactions of rhTPO in thrombocytopenia caused after chemotherapy of acute leukemia, and now the report is as below.